Extract
We thank Zhen-feng He and co-workers for their kind words about the EMBARC-India study. We agree that the predictors of outcome identified in the study may be useful to identify treatable traits in the Indian bronchiectasis population with potential relevance to other settings as well [1, 2].
Abstract
EMBARC-India identified distinct predictors of worse outcome in bronchiectasis in India. Future studies should investigate endotypes of inflammation in this population. https://bit.ly/3ukUeO6
Footnotes
Conflict of interest: J.D. Chalmers reports grants from AstraZeneca, Novartis, Boehringer Ingelheim, Insmed, GlaxoSmithKline and Gilead Sciences, and consulting fees from AstraZeneca, Insmed, Boehringer Ingelheim, Janssen, Chiesi, Novartis, GlaxoSmithKline, Pfizer and Zambon, outside the submitted work. R. Dhar has nothing to disclose.
Support statement: This work was supported by the European Respiratory Society. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received November 20, 2022.
- Accepted November 24, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
